Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Drug industry on tenterhooks as Maryland price-gouging law nears

share with twitter share with LinkedIn share with facebook
share via e-mail
09/15/2017 | 01:20pm CEST
A pharmacy employee dumps pills into a pill counting machine as she fills a prescription while working at a pharmacy in New York

(Reuters) - As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation's first law designed to punish drugmaker price-gouging.

The state Attorney General's office said it will field complaints and investigate "unconscionable increases" in essential generic medicines when the closely watched law takes effect Oct. 1.

Drugmakers fear the Maryland law will embolden other states and are seeking a court injunction. Both sides made their arguments on Thursday before a U.S. District Court judge in Baltimore, who could decide on an injunction in the coming days.

Anticipating the law will survive the legal challenge, the Attorney General's office said it is working with health economists at Johns Hopkins University to identify price spikes, which are not made public by drugmakers. Patient advocacy groups are urging consumers to report increased costs for their medicines. Maryland Citizens' Health Initiative will add an option to report price gouging to its website.

Pharmaceutical companies have so far dodged stricter federal oversight despite growing outrage over price hikes. Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) raised the price of heart medications Isuprel by about 720 percent and Nitropress by 310 percent, after acquiring them in 2015. Mylan NV (>> Mylan NV) raised the price of its life-saving EpiPen six-fold between 2008 and 2016.

But states, struggling to cover rising healthcare costs, are taking up the fight. At least 176 bills on pharmaceutical pricing and payment have been introduced this year in 36 states, according to the National Conference of State Legislatures.

Maryland's law is the most aggressive legislation to be passed so far, and allows the state to levy fines and order a reversal of price increases.

The Association for Accessible Medicines, a generic industry trade group that filed the lawsuit, argues that the law is unconstitutional because it does not define price-gouging and amounts to intervention by an individual state in interstate commerce.

"The issue of drug pricing is a national issue ... not something that should be handled piecemeal in 50 different ways," said Jeff Francer, general counsel for the trade group which represents companies like Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) and Novartis AG's (>> Novartis) Sandoz unit.

Maryland Attorney General Brian Frosh said that states have a well-defined role to play in policing "unconscionable" business activity against consumers, especially when they have no other recourse. He cited consumer contracts for telephone service, which are non-negotiable.


The measure applies only to older, off-patent drugs. Generic copies of branded products, usually much cheaper than the originals, account for around 89 percent of U.S. prescription volume, but only 26 percent of total drug spending, according to Quintiles IMS Holdings Inc (>> Quintiles IMS Holdings Inc).

But price spikes on some critical treatments have hit consumers hard. The U.S. Government Accountability Office last year found that 315 generic drugs more than doubled in price since 2010.

Maryland's Frosh said the aim is to deter future steep increases. Before the law was passed, drugmakers had suggested setting a minimum increase of 100 percent as a threshold for investigation, but state officials feared that would incentivize price hikes up to that point, according to Frosh’s office.

Several states have passed laws requiring drugmakers to disclose price increases, but the Maryland law is one of a few drawing the most attention from the drug industry.

Nevada has been sued by two industry trade groups after passing in June a law requiring diabetes drugmakers to justify price increases above a certain amount.

Ohio voters next year will decide on a ballot measure requiring drugmakers to offer state groups the same discounts given to the federal Department of Veterans Affairs. A similar measure failed in California last year, but the state's legislature this week approved a drug pricing bill requiring drugmakers to justify price increases over 16 percent in a two-year period. It now goes to the state's governor for a final decision.

"The states have decided to try and deal with this on their own," said David Gibbons an attorney at Hyman, Phelps & McNamara, which specializes in pharmaceutical and biotechnology companies.

(Reporting by Deena Beasley in Los Angeles; Editing by Michele Gershberg and Lisa Shumaker)

By Deena Beasley

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -0.69% 75.24 Delayed Quote.-8.06%
VALEANT PHARMACEUTICALS INTL INC 0.22% 22.39 Delayed Quote.-14.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN NV
03:11pCurrency and pricing squeeze GSK as new shingles vaccine shines
01:31pMYLAN : Adds to Growing Women's Healthcare Portfolio with Launch of Generic for ..
04/21MYLAN : Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at..
04/14MYLAN : EpiPen shortages seen in Canada, UK but U.S. supply intact
04/13Mylan in Talks to Acquire Merck KGaA's Consumer Health Business -Reuters
04/13MYLAN NV : Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics..
04/11MYLAN : Investor Day Highlights Durability of Mylan's Global Platform
04/11MYLAN : to Leverage its World-Class Scientific Platform to Develop a Novel Deliv..
04/11MYLAN : Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar..
04/10MYLAN : to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acet..
More news
News from SeekingAlpha
08:23aMylan launches generic version of Bayer's Yaz in U.S. 
04/20Teva Continues To Deliver But Analysts Stay Bearish 
04/19Novartis Q1 results weigh on pharma stocks 
04/18Tesla Looking For The Ramp Up, Theresa May Looking For The Exit Ramp (Wall St.. 
04/18WALL STREET BREAKFAST : Tesla Doubles Down On Model 3 
Financials ($)
Sales 2018 12 434 M
EBIT 2018 3 730 M
Net income 2018 1 963 M
Debt 2018 12 535 M
Yield 2018 -
P/E ratio 2018 11,60
P/E ratio 2019 9,85
EV / Sales 2018 2,70x
EV / Sales 2019 2,41x
Capitalization 20 993 M
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,9 $
Spread / Average Target 24%
EPS Revisions
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-3.62%20 993
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055